Grifols Plans IPO of U.S. Biopharma Business

Dow Jones03-25 15:53

By Adria Calatayud

Grifols said it plans an initial public offering of its U.S. biopharma business, as the Spanish pharmaceutical company seeks to raise money to bolster its balance sheet and fund investments.

Barcelona-based Grifols said late Tuesday that it would list a minority stake in the business and retain majority ownership within the parent company, which would maintain its listing in Spain.

The move aims to raise capital to support the company's debt-reduction efforts and investment in growth initiatives across key markets, the company said.

Grifols, which specializes in plasma-derived medicines, said it aims to tap into investor interest in a pure-play U.S. plasma company. Its U.S. biopharma business would have its own board and leadership team after the proposed IPO, the company added.

The business employs more than 14,000 people in the U.S., operates nearly 300 donation centers across 40 states and has industrial plants in California and North Carolina, Grifols said.

The proposed IPO remains subject to market conditions and regulatory approvals, the company said.

Write to Adria Calatayud at adria.calatayud@wsj.com

(END) Dow Jones Newswires

March 25, 2026 03:53 ET (07:53 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622302358?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 15:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622302358","market":"hk","top_or_hot":-1,"title":"Grifols Plans IPO of U.S. Biopharma Business","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adria Calatayud \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Grifols said it plans an initial public offering of its U.S. biopharma business, as the Spanish pharmaceutical company seeks to raise money to bolster its balance sheet and fund investments. \n</p>\n<p>\n  Barcelona-based Grifols said late Tuesday that it would list a minority stake in the business and retain majority ownership within the parent company, which would maintain its listing in Spain. \n</p>\n<p>\n  The move aims to raise capital to support the company's debt-reduction efforts and investment in growth initiatives across key markets, the company said. \n</p>\n<p>\n  Grifols, which specializes in plasma-derived medicines, said it aims to tap into investor interest in a pure-play U.S. plasma company. Its U.S. biopharma business would have its own board and leadership team after the proposed IPO, the company added. \n</p>\n<p>\n  The business employs more than 14,000 people in the U.S., operates nearly 300 donation centers across 40 states and has industrial plants in California and North Carolina, Grifols said. \n</p>\n<p>\n  The proposed IPO remains subject to market conditions and regulatory approvals, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adria Calatayud at adria.calatayud@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2026 03:53 ET (07:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grifols Plans IPO of U.S. Biopharma Business</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrifols Plans IPO of U.S. Biopharma Business\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-25 15:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adria Calatayud \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Grifols said it plans an initial public offering of its U.S. biopharma business, as the Spanish pharmaceutical company seeks to raise money to bolster its balance sheet and fund investments. \n</p>\n<p>\n  Barcelona-based Grifols said late Tuesday that it would list a minority stake in the business and retain majority ownership within the parent company, which would maintain its listing in Spain. \n</p>\n<p>\n  The move aims to raise capital to support the company's debt-reduction efforts and investment in growth initiatives across key markets, the company said. \n</p>\n<p>\n  Grifols, which specializes in plasma-derived medicines, said it aims to tap into investor interest in a pure-play U.S. plasma company. Its U.S. biopharma business would have its own board and leadership team after the proposed IPO, the company added. \n</p>\n<p>\n  The business employs more than 14,000 people in the U.S., operates nearly 300 donation centers across 40 states and has industrial plants in California and North Carolina, Grifols said. \n</p>\n<p>\n  The proposed IPO remains subject to market conditions and regulatory approvals, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adria Calatayud at adria.calatayud@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2026 03:53 ET (07:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2622302358","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622302358","pubTimestamp":1774425180,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Grifols said it plans an initial public offering of its U.S. biopharma business, as the Spanish pharmaceutical company seeks to raise money to bolster its balance sheet and fund investments.Barcelona-based Grifols said late Tuesday that it would list a minority stake in the business and retain majority ownership within the parent company, which would maintain its listing in Spain.The move aims to raise capital to support the company's debt-reduction efforts and investment in growth initiatives across key markets, the company said.Grifols, which specializes in plasma-derived medicines, said it aims to tap into investor interest in a pure-play U.S. plasma company. Its U.S. biopharma business would have its own board and leadership team after the proposed IPO, the company added.The business employs more than 14,000 people in the U.S., operates nearly 300 donation centers across 40 states and has industrial plants in California and North Carolina, Grifols said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GRFS":"基立福"},"translate_title":"Grifols计划美国生物制药业务IPO","themeId":"8603dabb40994e59ac78c04c930c0d49","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRFS":0.9},"content_text":"By Adria Calatayud \n\n\n \n\n\n  Grifols said it plans an initial public offering of its U.S. biopharma business, as the Spanish pharmaceutical company seeks to raise money to bolster its balance sheet and fund investments. \n\n\n  Barcelona-based Grifols said late Tuesday that it would list a minority stake in the business and retain majority ownership within the parent company, which would maintain its listing in Spain. \n\n\n  The move aims to raise capital to support the company's debt-reduction efforts and investment in growth initiatives across key markets, the company said. \n\n\n  Grifols, which specializes in plasma-derived medicines, said it aims to tap into investor interest in a pure-play U.S. plasma company. Its U.S. biopharma business would have its own board and leadership team after the proposed IPO, the company added. \n\n\n  The business employs more than 14,000 people in the U.S., operates nearly 300 donation centers across 40 states and has industrial plants in California and North Carolina, Grifols said. \n\n\n  The proposed IPO remains subject to market conditions and regulatory approvals, the company said. \n\n\n \n\n\n  Write to Adria Calatayud at adria.calatayud@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2026 03:53 ET (07:53 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622302358","isCrawlerRequest":true}